Рак желудка: факторы риска и возможности канцеропревенции


Цитировать

Полный текст

Аннотация

Среди всех злокачественных новообразований человека рак желудка (РЖ) находится на 4-м месте по частоте развития и на 2-м среди ведущих причин смертности от онкологических заболеваний во всем мире. Несмотря на динамику снижения заболеваемости в некоторых регионах мира, РЖ продолжает представлять собой серьезную клиническую проблему, так как в большинстве случаев заболевание диагностируется на поздних стадиях и ассоциировано с плохим прогнозом. Канцерогенез РЖ - сложный и многофакторный процесс, определяющийся разными каузативными и триггерными факторами, включая генетические и эпигенетические альтерации. К настоящему времени идентифицировано множество факторов риска развития РЖ, среди которых инфекция Helicobacter pylori, курение, высокое потребление соли и наследственная предрасположенность являются наиболее изученными. С учетом ключевой роли H. pylori в генезе РЖ эрадикация возбудителя рассматривается как основная тактика канцеропревенции.

Об авторах

Игорь Вениаминович Маев

ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России

д-р мед. наук, проф., чл.-кор. РАН, зав. каф. пропедевтики внутренних болезней и гастроэнтерологии

Дмитрий Николаевич Андреев

ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России

Email: dna-mit8@mail.ru
ассистент каф. пропедевтики внутренних болезней и гастроэнтерологии

Список литературы

  1. Abrams A.J, Wang T.C. Adenocarcinoma and other tumors of the stomach. In: Feldman M, Friedman L.S, Brandt L.J (eds): Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Management. 9th ed. Philadelphia: WB Saunders, 2010.
  2. Jemal A, Bray F, Center M.M et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
  3. Crew K.D, Neugut A.I. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12 (3): 354-62.
  4. Parkin D.M. International variation. Oncogene 2004; 23: 6329-40.
  5. Parkin D.M, Whelan S.L, Ferlay J. Cancer Incidence in Five Continents, vol VII. Lyon, France: International Agency for Research on Cancer, 1997: 822-3.
  6. Nomura A. Stomach Cancer. In: Schottenfeld D, Fraumeni J.F, eds. Cancer Epidemiology and Prevention. 2nd ed. New York: Oxford University Press, 1996: 707-24.
  7. Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9 (Suppl. 2): 45-51.
  8. Pandey R, Misra V, Misra S.P et al. Helicobacter pylori and gastric cancer. Asian Pac J Cancer Prev 2010; 11 (3): 583-8.
  9. Correa P. Helicobacter pylori and gastric cancer: state of the art. Cancer Epidemiol Biomarkers Prev 1996; 5: 477-81.
  10. Barreto-Zuniga R, Maruyama M, Kato Y et al. Significance of Helicobacter pylori infection as a risk factor in gastric cancer: serological and histological studies. J Gastroenterol 1997; 32: 289-94.
  11. Miehlke S, Hackelsberger A, Meining A et al. Histological diagnosis of Helicobacter pylori gastritis is predictive of a high risk of gastric carcinoma. Int J Cancer 1997; 73: 837-9.
  12. Nomura A.M, Stemmermann G.N, Chyou P.H. Gastric cancer among the Japanese in Hawaii. Jpn J Cancer Res 1995; 86: 916-23.
  13. Forman D, Newell D.G, Fullerton F et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 1991; 302: 1302-5.
  14. Kamangar F, Qiao Y.L, Blaser M.J et al. Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China. Br J Cancer 2007; 96:172-6.
  15. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
  16. Аруин Л.И. Из 100 инфицированных Helicobacter pylori РЖ возникает у двоих. Кто они? Эксперим. и клин. гастроэнтерология. 2004; 1: 12-8.
  17. Parsonnet J, Friedman G.D, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997; 40: 297-301.
  18. Hatakeyama M. Helicobacter pylori CagA and gastric cancer: a paradigm for hit - and - run carcinogenesis. Cell Host Microbe 2014; 15 (3): 306-16.
  19. Vicari J.J, Peek R.M, Falk G.W et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115: 50-7.
  20. Azuma T, Yamakawa A, Yamazaki S et al. Correlation between variation of the 3’ region of the CagA gene in Helicobacter pylori and disease outcome in Japan. J Infect Dis 2002; 186: 1621-30.
  21. Wroblewski L.E, Peek R.M.Jr. Helicobacter pylori in gastric carcinogenesis mechanisms. Gastroenterol Clin N Am 2013; 42: 285-98.
  22. Mowat C, Carswell A, Wirz A, Mc Coll K.E. Omeprazole and dietary nitrate independently affect levels of vitamin C and nitrite in gastric juice. Gastroenterology 1999; 116:813-22.
  23. Oldreive C, Rice-Evans C. The mechanisms for nitration and nitrotyrosine formation in vitro and in vivo: Impact of diet. Free Radic Res 2001; 35: 215-31.
  24. Sugimura T, Fujimura S, Baba T. Tumor production in the glandular stomach and alimentary tract of the rat by N-methyl-N -nitro- N-nitrosoguanidine. Cancer Res 1970; 30: 455-65.
  25. Bartsch H, Ohshima H, Pignatelli B, Calmels S. Human exposure to endogenous N-nitroso compounds: Quantitative estimates in subjects at high risk for cancer of the oral cavity, oesophagus, stomach and urinary bladder. Cancer Surv 1989; 8: 335-62.
  26. Knekt P, Jarvinen R, Dich J, Hakulinen T. Risk of colorectal and other gastro - intestinal cancers after exposure to nitrate, nitrite and N- nitroso compounds: A follow - up study. Int J Cancer 1999; 80: 852-6.
  27. Jakszyn P, Bingham S, Pera G et al. Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. Carcinogenesis 2006; 27:1497-501.
  28. Van Loon A.J, Botterweck A.A, Goldbohm R.A et al. Intake of nitrate and nitrite and the risk of gastric cancer: A prospective cohort study. Br J Cancer 1998; 78:129-35.
  29. Fox J.G, Dangler C.A, Taylor N.S et al. High - salt diet induces gastric epithelial hyperplasia and parietal cell loss, and enhances Helicobacter pylori colonization in C57BL/6 mice. Cancer Res 1999; 59: 4823-8.
  30. Correa P, Haenszel W, Cuello C et al. Gastric precancerous process in a high risk population: Cohort follow - up. Cancer Res 1990; 50: 4737-40.
  31. Ramon J.M, Serra L, Cerdo C, Oromi J. Dietary factors and gastric cancer risk. A case - control study in Spain. Cancer 1993; 71: 1731-5.
  32. Nazario C.M, Szklo M, Diamond E et al. Salt and gastric cancer: A case - control study in Puerto Rico. Int J Epidemiol 1993; 22: 790-7.
  33. Gonzalez C.A, Jakszyn P, Pera G et al. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006; 98: 345-54.
  34. Gonzalez C.A, Pera G, Agudo A et al. Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int J Cancer 2006; 118: 2559-66.
  35. Loh J.T, Torres V.J, Cover T.L. Regulation of Helicobacter pylori cagA expression in response to salt. Cancer Res 2007; 67: 4709-15.
  36. Gamboa-Dominguez A, Ubbelohde T, Saqui-Salces M et al. Salt and stress synergize H. pylori - induced gastric lesions, cell proliferation, and p21 expression in Mongolian gerbils. Dig Dis Sci 2007; 52:1517-26.
  37. Kuper H, Boffetta P, Adami H.O. Tobacco use and cancer causation: Association by tumour type. J Intern Med 2002; 252: 206-24.
  38. Gonzalez C.A, Pera G, Agudo A, et al. Smoking and the risk of gastric cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). Int J Cancer 2003; 107: 629-34.
  39. Sung N.Y, Choi K.S, Park E.C et al. Smoking, alcohol and gastric cancer risk in Korean men: The National Health Insurance Corporation Study. Br J Cancer 2007; 97: 700-4.
  40. Sjodahl K, Lu Y, Nilsen T.I et al. Smoking and alcohol drinking in relation to risk of gastric cancer: A population - based, prospective cohort study. Int J Cancer 2007; 120: 128-32.
  41. Ladeiras-Lopes R, Pereira A.K, Nogueira A et al. Smoking and gastric cancer: Systematic review and meta - analysis of cohort studies. Cancer Causes Control 2008; 19: 689-701.
  42. Freedman N.D, Abnet C.C, Leitzmann M.F et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol 2007; 165: 1424-33.
  43. Larsson S.C, Bergkvist L, Naslund I et al. Vitamin A, retinol, and carotenoids and the risk of gastric cancer: A prospective cohort study. Am J Clin Nutr 2007; 85: 497-503.
  44. Larsson S.C, Giovannucci E, Wolk A. Alcoholic beverage consumption and gastric cancer risk: a prospective population - based study in women. Int J Cancer 2007; 120: 373-7.
  45. Gammon M.D, Schoenberg J.B, Ahsan H et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997; 89: 1277-84.
  46. Renehan A.G, Tyson M, Egger M et al. Body - mass index and incidence of cancer: a systematic review and meta - analysis of prospective observational studies. Lancet 2008; 371: 569-78.
  47. Abnet C.C, Freedman N.D, Hollenbeck A.R et al. A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer 2008; 44: 465-71.
  48. Merry A.H, Schouten L.J, Goldbohm R.A, van den Brandt P.A. Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: A prospective cohort study. Gut 2007; 56: 1503-11.
  49. Mac Innis R.J, English D.R, Hopper J.L, Giles G.G. Body size and composition and the risk of gastric and oesophageal adenocarcinoma. Int J Cancer 2006; 118: 2628-31.
  50. Chow W.H, Blot W.J, Vaughan T.L et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998; 90:150-5.
  51. Lindblad M, Rodriguez L.A, Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non - cardia adenocarcinoma among men and women in a nested case - control study. Cancer Causes Control 2005; 16: 285-94.
  52. Zanghieri G, Di Gregorio C, Sacchetti C et al. Familial occurrence of gastric cancer in the 2-year experience of a population - based registry. Cancer 1990; 66: 2047-51.
  53. Brenner H, Arndt V, Sturmer T et al. Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma. Cancer 2000; 88: 274-9.
  54. Parsonnet J. When heredity is infectious. Gastroenterology 2000; 118: 222-4.
  55. Leung W.K, Ng E.K, Chan W.Y et al. Risk factors associated with the development of intestinal metaplasia in first - degree relatives of gastric cancer patients. Cancer Epidemiol Biomarkers Prev 2005; 14: 2982-6.
  56. Zwick A, Munir M, Ryan C.K et al. Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Gastroenterology 1997; 113: 659-63.
  57. Bianchi L.K, Burke C.A, Bennett A.E et al. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008; 6:180-5.
  58. Aarnio M, Salovaara R, Aaltonen L.A et al. Features of gastric cancer in hereditary non - polyposis colorectal cancer syndrome. Int J Cancer 1997; 74: 551-5.
  59. Coburn M.C, Pricolo V.E, De Luca F.G, Bland K.I. Malignant potential in intestinal juvenile polyposis syndromes. Ann Surg Oncol 1995; 2: 386-91.
  60. Howe J.R, Mitros F.A, Summers R.W. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 1998; 5: 751-6.
  61. Tamura G, Yin J, Wang S et al. E-cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 2000; 92: 569-73.
  62. Yoon K.A, Ku J.L, Yang H.K et al. Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. J Hum Genet 1999; 44: 177-80.
  63. El-Omar E.M, Carrington M, Chow W.H et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404:398-402.
  64. El-Omar E.M, Rabkin C.S, Gammon M.D et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124: 1193-201.
  65. Cheng D, Hao Y, Zhou W, Ma Y. Positive association between Interleukin-8 -251A>T polymorphism and susceptibility to gastric carcinogenesis: a meta - analysis. Cancer Cell Int 2013; 13 (1): 100.
  66. Wadhwa R, Song S, Lee J.S et al. Gastric cancer - molecular and clinical dimensions. Nat Rev Clin Oncol 2013; 10 (11): 643-55.
  67. Shimizu N, Ikehara Y, Inada K et al. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Res 2000; 60: 1512-4.
  68. Nozaki K, Shimizu N, Ikehara Y et al. Effect of early eradication on Helicobacter pylori - related gastric carcinogenesis in Mongolian gerbils. Cancer Sci 2003; 94: 235-9.
  69. Cai X, Carlson J, Stoicov C et al. Helicobacter felis eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice. Gastroenterology 2005; 128: 1937-52.
  70. You W.C, Brown L.M, Zhang L et al. Randomized double - blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006; 98: 974-83.
  71. Take S, Mizuno M, Ishiki K et al. The effect of eradicating helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 2005; 100: 1037e42.
  72. Fuccio L, Zagari R.M, Eusebi L.H et al. Meta - analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009; 151: 121e8.
  73. De Vries A.C, Kuipers E.J. Review article: helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 2007; 26(Suppl. 2): 25e35.
  74. De Vries A.C, Kuipers E.J. Epidemiology of premalignant gastric lesions: implications for the development of screening and surveillance strategies. Helicobacter 2007; 12 (Suppl. 2): 22-31.
  75. Wang J, Xu L, Shi R et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta - analysis. Digestion 2011; 83: 253e60.
  76. Rokkas T, Pistiolas D, Sechopoulos P et al. The long - term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta - analysis. Helicobacter 2007; 12 (Suppl. 2): 32e8.
  77. Howe L.R, Dannenberg A.J. A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol 2002; 29 (3 Suppl. 11):111-9.
  78. Saukkonen K, Rintahaka J, Sivula A et al. Cyclooxygenase-2 and gastric carcinogenesis. Apmis 2003; 111: 915-25.
  79. Wang W.H, Huang J.Q, Zheng G.F et al. Non - steroidal anti - inflammatory drug use and the risk of gastric cancer: a systematic review and meta - analysis. J Natl Cancer Inst 2003; 95 (23): 1784-91.
  80. Yang P, Zhou Y, Chen B et al. Aspirin use and the risk of gastric cancer: a meta - analysis. Dig Dis Sci 2010; 55 (6): 1533-9.
  81. Kobayashi M, Tsubono Y, Sasazuki S et al. Vegetables, fruit and risk of gastric cancer in Japan: A 10-year follow - up of the JPHC Study Cohort I. Int J Cancer 2002; 102: 39-44.
  82. Larsson S.C, Bergkvist L, Wolk A. Fruit and vegetable consumption and incidence of gastric cancer: A prospective study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1998-2001.
  83. Freedman N.D, Subar A.F, Hollenbeck A.R et al. Fruit and vegetable intake and gastric cancer risk in a large United States prospective cohort study. Cancer Causes Control 2008; 19: 459-67.
  84. Zhang Z, Xu G, Ma M et al. Dietary fiber intake reduces risk for gastric cancer: a meta - analysis. Gastroenterology 2013; 145: 113.
  85. Plummer M, Vivas J, Lopez G et al. Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: A randomized trial in a high - risk population. J Natl Cancer Inst 2007; 99: 137-46.
  86. Masuda M, Suzui M, Lim J.T, Weinstein I.B. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin Cancer Res 2003; 9: 3486-91.
  87. Henning S.M, Wang P, Carpenter C.L, Heber D. Epigenetic effects of green tea polyphenols in cancer. Epigenomics 2013; 5 (6): 729-41.
  88. Hou I.C, Amarnani S, Chong M.T, Bishayee A. Green tea and the risk of gastric cancer: epidemiological evidence. World J Gastroenterol 2013; 19 (24): 3713-22.

© ООО "Консилиум Медикум", 2014

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах